About the Company

Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin Limited is a Mumbai‑headquartered, innovation‑led transnational pharmaceutical company. Incorporated in 1983, the company develops, manufactures and markets a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs)  . Lupin has significant presence across Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro‑Intestinal, Anti‑Infectives and Nonsteroidal Anti‑Inflammatory Drug therapies, and is a global leader in Anti‑TB and Cephalosporins . Its products are distributed in over 100 markets, with strong presence across North America, EMEA, LATAM, APAC and India; operations span 112 countries as per the Business Responsibility and Sustainability Report  . Manufacturing locations are spread across India, USA, Mexico and Brazil, with 15 manufacturing sites and seven research centres supporting global supply and innovation fileciteturn5 .

As on March 31, 2025, Lupin had 32 subsidiaries worldwide (do not list names) and one joint venture, reflecting its diversified operating footprint and corporate structure  . Key milestones in the latest year included 41 product filings, 52 approvals and 87 patents secured, underscoring the company’s focus on complex generics and specialty portfolios across major markets .

Business Segments

– North America contributed 36 Per cent to revenues in FY25, affirming Lupin’s scale in the U.S. generics market .

– India contributed 34 Per cent to global turnover in FY25 .

– Other Developed Markets (Europe and Australia) contributed 11 Per cent of global revenues .

– Emerging Markets contributed 11 Per cent of global revenues .

– Domestic vs. International: On a standalone basis, exports comprised 53.9 Per cent of total sales in FY25 .

Key Management

– Manju D. Gupta – Chairperson

– Vinita Gupta – Chief Executive Officer

– Nilesh D. Gupta – Managing Director

– Ramesh Swaminathan – Executive Director, Global CFO, Head of IT and API Plus SBU

– Amit Kumar Gupta – Company Secretary

Latest Updates

– Portfolio and market expansion: Lupin acquired Eli Lilly’s Huminsulin and three diabetes products from Boehringer Ingelheim in India; it also acquired two specialty brands from Sanofi (Aarane in Germany and Nalcrom in Canada and the Netherlands) .

– Biologics progress: The company launched its first biosimilar, Rymti, in Canada and filed for Ranibizumab in the EU .

– Subsidiary additions: Lupin incorporated Lupin Lanka (Private) Limited in Sri Lanka and Lupin NZ Limited in New Zealand, expanding its presence in South Asia and Oceania .

– Pipeline momentum: In FY25, Lupin filed 41 products and received 52 approvals; 87 patents were secured, highlighting continued R&D intensity across inhalation, injectables, ophthalmic and oral segments .

– Regional performance highlights: North America sales grew 15.9 Per cent; Other Developed Markets rose 23.4 Per cent; Emerging Markets increased 6.8 Per cent, supported by differentiated portfolios and supply chain agility .